insulin novo nordisk - Search News

FDA Declares Shortage of Novo Nordisk's Wegovy, Ozempic

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

Hosted on MSN · 14h

Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.

STAT · 19h

Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.

4hon MSN

Why Novo Nordisk A/S (NVO) Surged On Friday?

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a ...

19h

Foes in FTC Insulin-Price Case Fire Off Subpoenas in Every Direction, From McDonald’s to Defense Department

After turning over more than 1,300 documents to the Federal Trade Commission, the fast food giant is turning its attention to subpoenas from pharmacy benefit managers the agency accuses of ...

Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

FiercePharma19h

Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift ...

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results